$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 17.42% on an annualized basis producing an average annual return of 29.68%. Currently, Regeneron
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
HC Wainwright analyst initiated coverage on AnaptysBio Inc (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering immunology therapeutics.AnaptysBio has a pipeline of checkpoint
US Stocks Rebound As Tech Surges, CrowdStrike Continues Selloff, Oil Hits 1-Month Lows: What's Driving Markets Monday?
Wall Street started the new week on a positive note, with all major indices in the green. A rebound in tech stocks following last week's dips bolstered overall investor sentiment. Investors focused on the start of the tech earnings season, looking past President Joe Biden's withdrawal from the reelection campaign.
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (
Breaking Down Gilead Sciences: 10 Analysts Share Their Views
Gilead Sciences (NASDAQ:GILD) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below offers a condensed view of their
Check Out What Whales Are Doing With MRNA
Investors with a lot of money to spend have taken a bullish stance on Moderna (NASDAQ:MRNA).And retail traders should know.We noticed this today when the trades showed up on publicly available
Regeneron Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 -7.62% Cantor Fitzgerald $925 → $1000 Maintains Neutral 07/19/2024 7.72% Piper Sandler $1000 →
IQVIA Posts Upbeat Earnings, Joins Terex, Reddit And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.Shares of IQVIA Holdings Inc. (NYSE:IQV) rose sharply during Monday's session after the company released better-
Gilead Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 -3.49% Cantor Fitzgerald $75 → $70 Maintains Neutral 07/08/2024 28.22% Raymond James → $93
Alnylam Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 -6.83% Cantor Fitzgerald $150 → $220 Maintains Neutral 07/12/2024 8% Morgan Stanley $250 → $255
IQVIA 'Is A Solid Investment' With Strong Competitive Positioning, Analyst Says After Better Than Expected Q2 Earnings
IQVIA Holdings Inc (NASDAQ:IQV) reported a second adjusted EPS of $2.64, up from $2.43, beating the consensus of $2.57.Provider of advanced analytics reported sales of $3.81 billion, beating the
Oppenheimer Outlined a Top Buy and Sell Idea for Each S&P Sector
Argenx Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 10.12% Wedbush $519 → $519 Reiterates Outperform → Outperform 07/17/2024 6.93% HC Wainwright &
Sector Update: Health Care Stocks Rise in Monday's Premarket Hours
Health care stocks were advancing premarket Monday with the Health Care Select Sector SPDR Fund (XLV) 0.3% higher and the iShares Biotechnology ETF (IBB) up 0.5% recently.IQVIA Holdings (IQV) was up
Earnings Summary: IQVIA Holdings Tops Q2 Consensus, Updates FY2024 Outlook
IQVIA Non-GAAP EPS of $2.64 Beats by $0.08, Revenue of $3.81B Beats by $20M
Here Are Big Pharma's Leading Blockbuster Makers
Check Out What Whales Are Doing With GILD
Whales with a lot of money to spend have taken a noticeably bullish stance on Gilead Sciences.Looking at options history for Gilead Sciences (NASDAQ:GILD) we detected 9 trades.If we consider the
IQVIA Q2 2024 Earnings Preview
How Is The Market Feeling About IQVIA Hldgs?
IQVIA Hldgs's (NYSE:IQV) short percent of float has fallen 5.39% since its last report. The company recently reported that it has 3.08 million shares sold short, which is 1.93% of all regular shares